Top

Published in:

01-07-2015 | Melanomas

Decreased Survival Rates of Older-Aged Patients with Melanoma: Biological Differences or Undertreatment?

Author: Charles M. Balch, MD, FACS

Published in: Annals of Surgical Oncology | Issue 7/2015

Excerpt

One of the most interesting unanswered questions in melanoma research is the paradoxical observation that melanomas among older patients have a different natural history and survival outcome compared with middle-aged and younger melanoma patients. Since 1978, a number of studies have published studies demonstrating that patient age is an independent predictive factor of melanoma survival, and that patient age independently predicts the incidence of sentinel node metastases among clinically node-negative patients.1‐4 …

Balch CM, Murad TM, Soong SJ, et al. A multifactorial analysis of melanoma: prognostic histopathological features comparing Clark’s and Breslow’s staging methods. Ann Surg. 1978;188:732–742.PubMedCentralPubMedCrossRef

Balch CM, Soong SJ, Gershenwald JE, et al. Age as a prognostic factor in patients with localized melanoma and regional metastases. Ann Surg Oncol. 2013;20:3961–3968.PubMedCentralPubMedCrossRef

Balch CM, Soong SJ, Gershenwald JE, et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol. 2001;19:3622–3634.PubMed

Balch CM, Thompson JF, Gershenwald JE, et al. Age as a predictor of sentinel node metastasis among patients with localized melanoma: an inverse correlation of melanoma mortality and incidence of sentinel node metastasis among young and old patients. Ann Surg Oncol. 2014;21:1075–1081.PubMedCentralPubMedCrossRef

Cavanaugh-Hussey MW, Mu EW, Kang S, et al. Older age is associated with a higher incidence of melanoma death but a lower incidence of sentinel lymph node metastasis in the SEER databases (2003–2011). Ann Surg Oncol. 2015. doi:10.1245/s10434-015-4538-8.PubMed

Sabel MS, Kozminski D, Griffith K, et al. Sentinel lymph node biopsy use among melanoma patients 75 years of age and older. Ann Surg Oncol. 2015. doi:10.1245/s10434-015-4539-7.PubMed

Chao C, Martin RC 2nd, Ross MI, et al. Correlation between prognostic factors and increasing age in melanoma. Ann Surg Oncol. 2004;11:259–264.PubMedCrossRef

Sondak VK, Taylor JM, Sabel MS, et al. Mitotic rate and younger age are predictors of sentinel lymph node positivity: lessons learned from the generation of a probabilistic model. Ann Surg Oncol. 2004;11:247–258.PubMedCrossRef

Balch CM, Soong SJ, Bartolucci AA, et al. Efficacy of an elective regional lymph node dissection of 1 to 4 mm thick melanomas for patients 60 years of age and younger. Ann Surg. 1996;224:255–263; discussion 263–256PubMedCentralPubMedCrossRef

10.

Morton DL, Thompson JF, Cochran AJ, et al. Final trial report of sentinel-node biopsy versus nodal observation in melanoma. N Engl J Med. 2014;370:599–609.PubMedCentralPubMedCrossRef

11.

Bilimoria KY, Balch CM, Wayne JD, et al. Health care system and socioeconomic factors associated with variance in use of sentinel lymph node biopsy for melanoma in the United States. J Clin Oncol. 2009;27:1857–1863.PubMedCrossRef

12.

Bilimoria KY, Balch CM, Bentrem DJ, et al. Complete lymph node dissection for sentinel node-positive melanoma: assessment of practice patterns in the United States. Ann Surg Oncol. 2008;15:1566–1576.PubMedCrossRef

13.

Tsai S, Balch C, Lange J. Epidemiology and treatment of melanoma in elderly patients. Nat Rev Clin Oncol. 2010;7:148–152.PubMedCrossRef

14.

Jemal A, Saraiya M, Patel P, et al. Recent trends in cutaneous melanoma incidence and death rates in the United States, 1992–2006. J Am Acad Dermatol. 2011;65:S17-25.e1-1CrossRef

15.

Geller AC, Miller DR, Annas GD, et al. Melanoma incidence and mortality among US whites, 1969-1999. JAMA. 2002;288:1719–1720.PubMedCrossRef

16.

Seidler AM, Pennie ML, Veledar E, et al. Economic burden of melanoma in the elderly population: population-based analysis of the Surveillance, Epidemiology, and End Results (SEER)–Medicare data. Arch Dermatol. 2010;146:249–256.PubMedCrossRef

17.

Balch CM, Gershenwald JE. Clinical value of the sentinel-node biopsy in primary cutaneous melanoma. N Engl J Med. 2014;370:663–664.PubMedCrossRef

18.

Balch CM, Morton DL, Gershenwald JE, et al. Sentinel node biopsy and standard of care for melanoma. J Am Acad Dermatol. 2009;60:872–875.PubMedCrossRef

19.

Wong SL, Balch CM, Hurley P, et al. Sentinel lymph node biopsy for melanoma: American Society of Clinical Oncology and Society of Surgical Oncology joint clinical practice guideline. Ann Surg Oncol. 2012;19:3313–3324.PubMedCrossRef

Title: Decreased Survival Rates of Older-Aged Patients with Melanoma: Biological Differences or Undertreatment?
Author: Charles M. Balch, MD, FACS
Publication date: 01-07-2015
Publisher: Springer US
Published in: Annals of Surgical Oncology / Issue 7/2015
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI: https://doi.org/10.1245/s10434-015-4540-1

At a glance: The STEP trials

Springer Medicine

Decreased Survival Rates of Older-Aged Patients with Melanoma: Biological Differences or Undertreatment?

Excerpt

At a glance: The STEP trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 7/2015

A Prospective Evaluation of Lymphedema-Specific Quality-of-Life Outcomes Following Vascularized Lymph Node Transfer

Surgical Outcomes of Hepatic Resection for Hepatitis B Virus Surface Antigen-Negative and Hepatitis C Virus Antibody-Negative Hepatocellular Carcinoma

Ipsilateral Central Neck Dissection Plus Frozen Section Examination Versus Prophylactic Bilateral Central Neck Dissection in cN0 Papillary Thyroid Carcinoma

Comparison of mRNA, Protein, and Urinary Nucleic Acid Levels of S100A8 and S100A9 between Prostate Cancer and BPH

Second Axillary Sentinel Lymph Node Biopsy for Breast Tumor Recurrence: Experience of the European Institute of Oncology

High Expression of Cathepsin E in Tissues but Not Blood of Patients with Barrett’s Esophagus and Adenocarcinoma